Solid Tumors

Solid Tumors

FDA Approves Pimicotinib for Symptomatic TGCT

November 10 3 min read
On November 10, pimicotinib (Pimjetmi), a kinase inhibitor, was approved for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may cause worsening functional limitation or severe morbidity.

Latest in Solid Tumors